1-3 of 3
Mark R. Bray, PhD
Close
Sort by
Journal Articles

The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo , and Shows Synergistic Activity in Combination with Lenalidomide

Xiaojing Wang, PhD, Anthony L. Sinn, Attaya Suvannasankha, MD, Colin D. Crean, Li Chen, MD, Shuhong Zhang, PhD, Jing Liang, MD, Genglin Zhang, Karen E. Pollok, PhD, Rafat Abonour, MD, Carolyn Sidor, MD, Mark R. Bray, PhD, Sherif S. Farag, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3660.
https://doi.org/10.1182/blood.V112.11.3660.3660
Published: 2008
Journal Articles

MKC-1 Is a Novel Agent That Induces Cell Cycle Arrest and Disrupts Multiple Survival Pathways in Hematologic Cancers.

Trisha A. Denny, Xiaoru Chen, Cassandra L. Waters, Patricia A. Burke, PhD, Graham C. Fletcher, PhD, John Xu, PhD, Carolyn F. Sidor, MD, MBA, Mark D. Minden, MD, PhD, Theresa M. LaVallee, PhD, Mark R. Bray, PhD
Journal: Blood
Blood (2006) 108 (11): 4390.
https://doi.org/10.1182/blood.V108.11.4390.4390
Published: 2006
Journal Articles

ENMD-981693 Is an Orally-Active Kinase Inhibitor with Activity towards Human Hematologic Cancers In Vitro and In Vivo .

Mark R. Bray, PhD, Graham C. Fletcher, PhD, Trisha A. Denny, John Xu, PhD, Xiaoru Chen, Patricia A. Burke, PhD, Wanda Franklin, Theresa M. LaVallee, PhD, Mark D. Minden, MD, PhD, Carolyn F. Sidor, MD, MBA
Journal: Blood
Blood (2006) 108 (11): 1377.
https://doi.org/10.1182/blood.V108.11.1377.1377
Published: 2006